A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis
GlaxoSmithKline
363 participants
Oct 30, 2025
INTERVENTIONAL
Conditions
Summary
This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be administered with dose level 1 of GSK3862995B.
Participants will be administered with matching placebo.
Locations(134)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07201051